Nu-Med Plus (NUMD) Cash & Equivalents Growth (1y) (2012 - 2025)
Nu-Med Plus (NUMD) Cash & Equivalents Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.45 Bn | 193.85 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.62 Bn | 124.14 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.41 Bn | 72.87 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.89 Bn | 47.64 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.33 Bn | 32.38 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.87 Bn | 31.76 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 72.43% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | 526.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.14% |
| Sep 30, 2025 | -51.79% |
| Jun 30, 2025 | -78.64% |
| Mar 31, 2025 | -62.67% |
| Dec 31, 2024 | -65.13% |
| Sep 30, 2024 | -63.56% |
| Jun 30, 2024 | -86.51% |
| Mar 31, 2024 | -88.01% |
| Dec 31, 2023 | -90.70% |
| Sep 30, 2023 | 1,665.61% |
| Mar 31, 2023 | 1,990.22% |
| Dec 31, 2022 | 526.94% |
| Sep 30, 2022 | -98.03% |
| Mar 31, 2022 | -98.18% |
| Dec 31, 2021 | -93.81% |
| Sep 30, 2021 | 1.09% |
| Jun 30, 2021 | 1,092.78% |
| Mar 31, 2021 | 659.85% |
| Dec 31, 2020 | 2,562.89% |
| Sep 30, 2020 | -24.71% |